MYRIAD GENETICS DL-,01 | 17,820 / 0,00% |
日期/时间 | 04.07. / 21:43 |
涨跌。 / 涨跌。(%) | 0,000 / 0,00% |
Bid | 17,745 / 150 |
Ask | 17,885 / 150 |
打开 | 17,820 |
以往收市 | 17,820 |
高 | 17,820 |
低 | 17,820 |
成交量 [EUR] | - |
成交量 [Units] | |
Price fixings | 9 |
ISIN | US62855J1043 |
符号 | MYD |
交易所 | gettex |
类型 | 股票 |
所有交易
交易所 | 最后的 | 成交量 | |
---|---|---|---|
Lang & Schwa.. | 17,720 | ![]() |
|
Xetra | 17,800 | ![]() |
0 |
Hannover | 17,690 | ![]() |
0 |
Frankfurt | 17,6850 | ![]() |
0 |
Berlin | 17,700 | ![]() |
0 |
München | 17,690 | ![]() |
0 |
Hamburg | 17,690 | ![]() |
0 |
Düsseldorf | 17,765 | ![]() |
0 |
Stuttgart | 17,735 | ![]() |
0 |
gettex | 17,820 | ![]() |
|
Quotrix | 17,7750 | ![]() |
|
NASDAQ | 18,6300 | ![]() |
439.907 |
IEX | 18,60 | ![]() |
22.765 |
Cboe US | 18,60 | ![]() |
9.352 |
London Domes.. | 19,45 | 31 | |
TradeGate | 16,450 | 600 |
新闻
- Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
14.03.2022 / 12:05 - GlobeNewswire - Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
12.03.2022 / 01:05 - GlobeNewswire - Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
08.03.2022 / 13:22 - GlobeNewswire - Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference
02.03.2022 / 22:30 - GlobeNewswire - Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
24.02.2022 / 15:00 - GlobeNewswire
Personal area
Click on
to activate push quotes.
